MX2020012628A - Compuestos organicos. - Google Patents

Compuestos organicos.

Info

Publication number
MX2020012628A
MX2020012628A MX2020012628A MX2020012628A MX2020012628A MX 2020012628 A MX2020012628 A MX 2020012628A MX 2020012628 A MX2020012628 A MX 2020012628A MX 2020012628 A MX2020012628 A MX 2020012628A MX 2020012628 A MX2020012628 A MX 2020012628A
Authority
MX
Mexico
Prior art keywords
organic compounds
pde1
gliomas
tumors
inhibitors
Prior art date
Application number
MX2020012628A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence P Wennogle
Joseph Hendrick
Robert Davis
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2020012628A publication Critical patent/MX2020012628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020012628A 2018-05-25 2019-05-24 Compuestos organicos. MX2020012628A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676638P 2018-05-25 2018-05-25
US201862688641P 2018-06-22 2018-06-22
PCT/US2019/033941 WO2019227004A1 (en) 2018-05-25 2019-05-24 Organic compounds

Publications (1)

Publication Number Publication Date
MX2020012628A true MX2020012628A (es) 2021-01-29

Family

ID=68616034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012628A MX2020012628A (es) 2018-05-25 2019-05-24 Compuestos organicos.

Country Status (11)

Country Link
US (1) US20210205310A1 (https=)
EP (2) EP4520399A3 (https=)
JP (1) JP7493460B2 (https=)
KR (1) KR20210013214A (https=)
CN (1) CN112189013A (https=)
AU (1) AU2019275453B2 (https=)
BR (1) BR112020024037A2 (https=)
CA (1) CA3099283A1 (https=)
IL (2) IL278935B2 (https=)
MX (1) MX2020012628A (https=)
WO (1) WO2019227004A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
JP2005289891A (ja) * 2004-03-31 2005-10-20 Zen Kubohara Ｐｄｅ１阻害剤
US7783679B2 (en) 2005-01-12 2010-08-24 Computer Associates Think, Inc. Efficient processing of time series data
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (en) 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6224597B2 (ja) * 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
EP2968338B1 (en) * 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US20160045617A1 (en) * 2013-04-10 2016-02-18 Justin C. Lee Treatment of proximal spinal muscular atrophy
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP6696904B2 (ja) * 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
KR20160138084A (ko) 2014-04-04 2016-12-02 하. 룬드벡 아크티에셀스카브 Pde1 저해제인 할로겐화된 퀴나졸린-thf-아민
EP3157926B1 (en) * 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN110267908B (zh) 2016-09-12 2023-08-22 麦斯卓微电子(南京)有限公司 Mems致动系统和方法
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US10918628B2 (en) * 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
WO2018093591A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
IL278935A (en) 2021-01-31
IL278935B1 (en) 2025-12-01
US20210205310A1 (en) 2021-07-08
WO2019227004A1 (en) 2019-11-28
KR20210013214A (ko) 2021-02-03
EP4520399A3 (en) 2025-03-26
CA3099283A1 (en) 2019-11-28
JP2021525705A (ja) 2021-09-27
EP4520399A2 (en) 2025-03-12
IL322048A (en) 2025-09-01
IL278935B2 (en) 2026-04-01
JP7493460B2 (ja) 2024-05-31
AU2019275453B2 (en) 2023-12-21
EP3802545A4 (en) 2022-03-16
CN112189013A (zh) 2021-01-05
EP3802545A1 (en) 2021-04-14
AU2019275453A1 (en) 2020-12-03
BR112020024037A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
NZ784224A (en) Parp1 inhibitors
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2025011533A (es) Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
PH12017502002A1 (en) 5`-substituted nucleoside analogs
NZ730771A (en) Aurora a kinase inhibitor
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
AU2018380132A8 (en) Tubulin inhibitors
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
WO2019023315A3 (en) Rac inhibitors
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2019008773A (es) Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2022002607A (es) Metodos de tratamiento.